Barclays analyst Eliana Merle raised the firm’s price target on Ionis Pharmaceuticals (IONS) to $115 from $106 and keeps an Overweight rating on the shares.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IONS:
- Ionis Pharmaceuticals’ Earnings Call Flags Growth and Risks
- Analyst Reiterates Buy Rating on Ionis Pharmaceuticals, Maintains $105 Price Target on Strong Q1 and Upgraded Olezarsen Outlook
- Ionis Pharmaceuticals reports Q1 EPS (56c), consensus (77c)
- Ionis Pharmaceuticals raises FY26 revenue view $875M-$900M from $800M-$825M
- Ionis partner GSK announces bepirovirsen NDA accepted for priority review